TL/DR –
The U.S. Department of Health and Human Services Office of Inspector General (OIG) approved a proposed arrangement for a nonprofit, tax-exempt charity to provide health insurance premium assistance and copayment help to patients with rare and chronic diseases, funded partly by pharmaceutical manufacturers. The OIG’s approval was based on several measures including the charity’s independence from manufacturer donors, uniform financial need criteria, and a first-come, first-served allocation system. In a potentially significant move, the OIG connected the Inflation Reduction Act’s Part D cost-sharing reforms to its fraud and abuse analysis, thereby signaling that these reforms may reshape the patient assistance program landscape.
“`html
Charitable Organization’s Patient Assistance Program Secure OIG Approval
A proposed initiative by a nonprofit, tax-exempt charitable organization, providing health insurance premium aid and copayment assistance to patients with rare chronic diseases, has been given the green light by the Office of Inspector General (OIG). The funds for this program would be partially sourced from pharmaceutical manufacturers, according to Advisory Opinion 26-17.
The Key Points of the OIG Approval
The OIG’s approval of the proposed scheme was not without its stipulations. Some of the key considerations include the independence of the organization from manufacturer donors, clear disease fund definitions, uniform financial need criteria, a first-come, first-served approach, and a prohibition on data sharing that could enable donors to link donations with product use. The OIG also pointed to the Inflation Reduction Act’s (IRA’s) Part D redesign provisions and reserved the right to reevaluate the setup in approximately two years. This signaled the potential implications of the IRA’s structural changes for the patient assistance program landscape.
The Substance of the Approved Arrangement
The initiative would offer health insurance premium aid and copayment assistance for prescription medications for patients with specific rare and chronic illnesses. Interestingly, the advisory opinion is of note not due to the conclusion but because of a footnote referencing the IRA’s Part D redesign provisions, thus introducing a new variable into the compliance environment for manufacturer-funded patient assistance programs (PAPs).
Arrangement Details
The charitable organization proposes to establish funds for each disease covered under their program. These funds would provide health insurance premium aid and copayment and coinsurance assistance for prescription medications. The organization provided data showing that the diseases targeted by the program impose remarkable financial burdens on patients. The suggested arrangement included specifics such as division of disease funds, patient choice of healthcare providers, and independence from manufacturers, among others.
OIG Analysis
While the OIG acknowledges the significant assistance independent charity PAPs can provide, they also identified the fraud and abuse risks associated with them. The OIG analyzed the Proposed Arrangement under the federal Anti-Kickback Statute and came to the conclusion that the Proposed Arrangement poses a low risk of fraud and abuse. Factors leading to this conclusion include the lack of data sharing and independence from manufacturers, among others.
Significance of the OIG’s Reference to IRA’s Part D Redesign
The most notable part of Advisory Opinion 26-17, unexpectedly, is not the conclusion but the fact that the OIG explicitly connected the IRA’s Part D cost-sharing reforms to its fraud and abuse analysis, signaling that it is actively keeping an eye on how the IRA’s Part D redesign could alter the patient assistance program landscape.
Implications for PAP Operators and Pharmaceutical Manufacturers
Advisory Opinion 26-17 emphasizes the continuing importance of traditional PAP safeguards, while introducing new considerations tied to the IRA’s Part D redesign. Organizations contributing to or evaluating PAPs should assess whether the PAP includes the safeguards highlighted in Advisory Opinion 26-17, as well as how the IRA’s Part D reforms may affect demand for and the structure of the PAP’s assistance. It provides important insight regarding OIG’s evolving perspective on the interplay between the IRA’s Part D redesign and manufacturer-funded patient assistance programs.
This article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
[View Source]
“`
—
Read More US Economic News